Acquisition adds seven

收购新增七项

commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol),

包括VABYSMO®（法瑞西单抗-svoa）、OJEMDA™（托沃拉非尼）和MIPLYFFA®（阿里莫克莫尔）在内的商业产品，

and

和

more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth

拥有100多项处于开发和商业化阶段的资产，创造推动增长的长期机遇

Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026

Ligand 将在 2026 年 12 月 8 日的投资者日上提供更新后的五年展望

JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.

佛罗里达州朱庇特，2026年7月14日（环球电讯社）——Ligand Pharmaceuticals Incorporated（纳斯达克股票代码：LGND）今日宣布，已完成对生物技术特许权使用费聚合商XOMA Royalty Corporation（“XOMA Royalty”）的收购，收购价格为每股普通股39.00美元现金，总股权价值约为7.39亿美元。

XOMA Royalty stockholders also received one non-transferable Contingent Value Right (“CVR”) per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending litigation at XOMA Royalty..

XOMA Royalty 的股东还按每股获得一项不可转让的或有价值权（“CVR”），使持有人有权获得 XOMA Royalty 某些未决诉讼可能产生的净收益中 75% 的一部分。

“At Ligand, we are focused on building a diversified portfolio of high-value royalty assets tied to innovative medicines that have the potential to improve patient outcomes around the world,” said Todd Davis, CEO of Ligand. “Over the past several years, we have executed a disciplined strategy to expand, diversify and strengthen our royalty portfolio, and the acquisition of XOMA Royalty meaningfully advances that vision.

Ligand 首席执行官 Todd Davis 表示：“在 Ligand，我们专注于构建一个多元化的高价值特许权使用费资产组合，这些资产与创新药物挂钩，有望改善全球患者的治疗结果。在过去几年中，我们执行了一项严谨的战略，以扩展、多元化并加强我们的特许权使用费资产组合，而收购 XOMA Royalty 则有力地推进了这一愿景。”

This transaction adds exposure to high-quality commercial and development-stage assets and enhances our ability to generate durable, long-term shareholder value, marking an important milestone in our evolution as a leading biopharmaceutical royalty aggregator.”.

“此次交易增加了对高质量商业阶段和开发阶段资产的敞口，提升了我们创造持久、长期股东价值的能力，标志着我们在成为领先生物医药特许权使用费整合商的演进过程中迈出了重要里程碑。”

This acquisition strengthens Ligand’s royalty portfolio by adding seven commercial products, including Roche’s VABYSMO® (faricimab-svoa), Servier’s OJEMDA™ (tovorafenib), and Zevra Therapeutics’ MIPLYFFA® (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.

此次收购通过增加七款商业化产品，强化了Ligand公司的特许权使用费组合，其中包括罗氏的VABYSMO®（faricimab-svoa）、施维雅的OJEMDA™（tovorafenib）以及Zevra Therapeutics的MIPLYFFA®（arimoclomol）。此外，该交易还涵盖14个后期开发项目，包括武田制药的mezagitamab以及武田外部化资产组合中的某些资产（如osavampator、volixibat和OHB-607），以及100多个处于不同开发阶段的资产。

As a result, Ligand’s portfolio has more than doubled in size, now comprising over 200 commercial, clinical, and preclinical stage royalty assets..

因此，Ligand 的产品组合规模已增长一倍以上，目前包含超过200项处于商业化、临床及临床前阶段的 royalty 资产。

The closing of the transaction met Ligand’s original timeline expectations. The transaction is expected to be immediately accretive and to add approximately $0.50 and $1.50 per share to Ligand’s projected 2026 and 2027 adjusted earnings per share

该交易的完成符合Ligand公司最初的时间表预期。预计该交易将立即增厚收益，并使Ligand公司2026年和2027年预测的调整后每股收益分别增加约0.50美元和1.50美元。

1

1

, respectively. Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.

分别。Ligand 将在 2026 年 12 月 8 日的公司投资者日上提供更新后的五年期展望。

In connection with the completion of the transaction, XOMA Royalty common stock ceased trading on The Nasdaq Global Market.

随着交易的完成，XOMA Royalty 的普通股在纳斯达克全球市场停止交易。

Advisors

顾问

Stifel served as lead financial advisor, Citi served as financial advisor, Paul Hastings LLP served as legal advisor, and Collected Strategies served as strategic communications advisor to Ligand. Leerink Partners served as lead financial advisor, H.C. Wainwright & Co. served as financial advisor, and Gibson, Dunn & Crutcher LLP served as legal advisor to XOMA Royalty..

Stifel 担任 Ligand 的首席财务顾问，Citi 担任财务顾问，Paul Hastings LLP 担任法律顾问，Collected Strategies 担任战略传播顾问。Leerink Partners 担任 XOMA Royalty 的首席财务顾问，H.C. Wainwright & Co. 担任财务顾问，Gibson, Dunn & Crutcher LLP 担任法律顾问。

About Ligand

关于配体

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets.

Ligand 是一家领先的特许权使用费聚合商，与生物制药公司合作，为后期临床开发项目提供资金并推动其进展。Ligand 拥有并管理着行业内规模最大、最多样化的生物制药特许权使用费组合之一，在200多个开发和商业化阶段资产中拥有经济权益。

Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network.

Ligand 通过获取长期经济利益，为高价值项目提供资金支持，实现资本与临床及商业成功的一致性。Ligand 的特许权使用费组合旨在通过广泛的治疗资产组合，提供稳定且可预测的收入流。此外，Ligand 还向其全球合作伙伴网络授权其专有技术 Captisol® 和 NITRICIL™，以支持药物开发和制剂研究。

For more information, visit .

更多信息，请访问。

www.ligand.com

www.ligand.com

or follow Ligand on

或在以下平台关注 Ligand

X

X

and

和

LinkedIn

领英

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, Ligand’s acquisition of XOMA Royalty, Ligand’s and XOMA Royalty’s products pipeline and the substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所定义的“前瞻性陈述”，这些陈述涉及重大风险和不确定性，包括（但不限于）关于Ligand收购XOMA Royalty、Ligand和XOMA Royalty的产品管线，以及可能导致实际结果与此类陈述明示或暗示的结果存在重大差异的重大风险和不确定性的信息。

Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; the risk that XOMA Royalty stockholders may receive no payment with respect to the CVRs; disruption from the transaction making it more difficult to maintain business and operational relationships, including the ability to attract and retain highly qualified management and other clinical and scientific personnel; negative effects of this announcement or the completion of the acquisition on the market price of Ligand’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the acquisition of XOMA Royalty’s business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy; changes in tax and other laws, regulations, rates and polic.

风险和不确定性包括但不限于：与实现收购预期收益能力相关的风险，包括可能无法实现或无法在预期时间内实现收购的预期收益；业务整合失败的风险；XOMA Royalty 股东可能无法获得与或有价值权（CVRs）相关的任何付款的风险；交易造成的干扰使得维持业务和运营关系更加困难，包括吸引和留住高素质管理人员及其他临床和科研人员的难度增加；本次公告或收购完成对 Ligand 普通股市场价格和/或经营业绩的负面影响；重大的交易成本；未知负债；与收购 XOMA Royalty 业务相关的诉讼和/或监管行动风险；其他商业影响和不确定性，包括行业、市场、商业、经济、政治或监管状况的影响；未来汇率和利率；与已发布或未来的行政命令或其他新颁布或变更的法律、法规或政策相关的风险和不确定性；税收及其他法律、法规、税率和政策的变化。

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Ligand and XOMA Royalty described in the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” (in the case of Ligand) and “Forward Looking Statements” (in the case of XOMA Royalty) sections of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the U.S.

您应仔细考虑前述因素以及影响 Ligand 和 XOMA Royalty 业务的其他风险和不确定性，这些因素在其各自的 Form 10-K 年度报告、Form 10-Q 季度报告以及不时向美国提交的其他文件中的“风险因素”和“关于前瞻性陈述的警示说明”（针对 Ligand）或“前瞻性陈述”（针对 XOMA Royalty）章节中有所描述。

Securities and Exchange Commission (the “SEC”), all of which are available at .

证券交易委员会（“SEC”），所有这些文件均可在 获取。

www.sec.gov

www.sec.gov

. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ligand assumes no obligation to, and does not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

。这些文件识别并阐述了其他重要的风险和不确定性，这些因素可能导致实际事件和结果与前瞻性陈述中包含的内容存在重大差异。前瞻性陈述仅在其发表之日有效。提醒读者不要过度依赖前瞻性陈述，除非法律另有要求，Ligand 不承担且无意因新信息、未来事件或其他原因更新或修订这些前瞻性陈述。

Ligand gives no assurance that it will achieve its expectations..

Ligand 不保证其预期能够实现。

Contacts

联系人

Investors:

投资者：

Melanie Herman

梅兰妮·赫尔曼

investors@ligand.com

investors@ligand.com

(858) 550-7761

(858) 550-7761

Media:

媒体：

Nick Lamplough/Jude Gorman

尼克·兰普劳/朱德·戈尔曼

Ligand-CS@collectedstrategies.com

Ligand-CS@collectedstrategies.com

(917) 885-1013

(917) 885-1013

1

1

The financial outlook, expectations and other forward-looking statements provided by Ligand for 2026 and beyond reflect Ligand's judgment based on the information available at the time of this release. Please see the Forward-looking Statements section in this release for factors that may impact Ligand's ability to meet expectations.

Ligand 就 2026 年及以后期间提供的财务前景、预期及其他前瞻性陈述，反映了其基于本发布时可获信息所作出的判断。请参阅本发布中的“前瞻性陈述”部分，了解可能影响 Ligand 实现预期能力的因素。

In reliance upon Item 10(e)(1)(i)(B) of Regulation S-K, reconciliations of forward-looking core adjusted earnings per diluted share for 2027 is not provided because of the unreasonable effort associated with providing such reconciliations due to the variability in the occurrence and the amounts of certain components thereof.

依据《S-K条例》第10(e)(1)(i)(B)项，由于某些组成部分的发生情况及其金额存在变数，提供此类调节表将导致不合理的努力，因此未提供2027年前瞻性核心调整后稀释每股收益的调节表。

For the same reasons, we are unable to address the significance of the unavailable information, which could be material to future results..

出于同样的原因，我们无法评估无法获取的信息的重要性，而这些信息可能对未来的业绩具有重大影响。